Vimarsana
Biggest News Aggregation in the World

Page 3 - Why Target News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Why Target. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Why Target Today - Breaking & Trending Today

Calliditas Therapeutics: Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 - Vimarsana News

Calliditas Therapeutics: Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Published: May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study

Source: finanznachrichten.de
Related Topics:
United KingdomUnited StatesRichard PhilipsonRichard LafayetteKaren MolyneuxUniversity Of LeicesterExchange CommissionEuropean Renal AssociationEuropean CommissionNasdaq StockholmNeflgard PhaseNefigard PhasePresentation DetailsStanford HealthcareKidney InflammationIga NephropathyPoster DetailsFull PrescribingPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor RelationsCalliditas TherapeuticsWhy Target
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (1) - Vimarsana News

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (1)

Published: May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United KingdomUnited StatesKaren MolyneuxRichard LafayetteRichard PhilipsonEuropean Renal AssociationExchange CommissionEuropean CommissionUniversity Of LeicesterNasdaq StockholmNeflgard PhaseNefigard PhasePresentation DetailsStanford HealthcareKidney InflammationIga NephropathyPoster DetailsFull PrescribingPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor RelationsCalliditas TherapeuticsWhy Target
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 - Vimarsana News

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Published: May 5, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd...

Source: prnewswire.com
Related Topics:
United KingdomUnited StatesKaren MolyneuxRichard LafayetteRichard PhilipsonEuropean Renal AssociationExchange CommissionEuropean CommissionUniversity Of LeicesterCalliditas TherapeuticsNasdaq StockholmNeflgard PhaseNefigard PhasePresentation DetailsStanford HealthcareKidney InflammationIga NephropathyPoster DetailsFull PrescribingPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor RelationsWhy Target
Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (2) - Vimarsana News

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023 (2)

Published: May 5, 2023

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX)...

Source: europapress.es
Related Topics:
United KingdomUnited StatesRichard PhilipsonKaren MolyneuxRichard LafayetteEuropean CommissionUniversity Of LeicesterExchange CommissionEuropean Renal AssociationNasdaq StockholmNeflgard PhaseNefigard PhasePresentation DetailsStanford HealthcareKidney InflammationIga NephropathyPoster DetailsFull PrescribingPrimary ImmunoglobulinAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActInvestor RelationsCalliditas TherapeuticsWhy Target
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy - Vimarsana News

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

Published: March 13, 2023

/PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas") today announced positive topline results from the global,...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomMarie GalayVilla BacaExchange CommissionKidney InternationalEuropean CommissionNefigard ToplineFull Prescribing InformationPrimary ImmunoglobulinNasdaq StockholmAmerican Depositary SharesNasdaq Global Select MarketPrivate Securities Litigation Reform ActCalliditas TherapeuticsLife ExpectancyPatients FromSoutheastern United States With IgaKidney Int RepNefigard Trial InvestigatorsWhy TargetTreat IgaIga NephropathyNationwide Population Based CohortHealth Care Amp Hospitals